Canada markets close in 3 hours 4 minutes

GRTS Aug 2022 10.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
5.800.00 (0.00%)
As of 03:48PM EDT. Market open.
Full screen
Previous Close5.80
Open5.80
Bid5.10
Ask5.90
Strike10.00
Expire Date2022-08-19
Day's Range5.80 - 5.80
Contract RangeN/A
Volume20
Open Interest46
  • GlobeNewswire

    Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    EMERYVILLE, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors granted eight employees nonqualified stock options to purchase an aggregate of 239,100 shares of its common stock with an exercise price of $3.40, which is equal to the closing price of Gritstone’s common stock on August 10, 2022, the date of the grant. These st

  • GlobeNewswire

    Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors

    -- Paper reports that Gritstone’s tumor-specific, neoantigen vaccination approach drives priming and boosting of tumor-specific T cells, including cytotoxic CD8+ T cells -- -- T cells linked to molecular responses in advanced colorectal cancer (CRC) patients and associated with extended overall survival, which has been observed in follow-up to the Phase 1/2 study -- -- GRANITE now in a randomized, controlled Phase 2/3 trial in newly diagnosed metastatic, microsatellite-stable colorectal cancer (

  • GlobeNewswire

    Gritstone Appoints Dr. Lawrence “Larry” Corey to its Board of Directors

    -- Expert in virology, immunology and vaccine development’s appointment effective August 12 -- Dr. Lawrence "Larry" Corey Dr. Lawrence "Larry" Corey, M.D., expert in virology, immunology and vaccine development and incoming Board Member of Gritstone bio, Inc. EMERYVILLE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced the appointment of Lawrence “Larry” Core